Reply  by Mueller, Thomas & Haltmayer, Meinhard
LETTERS TO THE EDITORRegarding “Serum total 8-iso-prostaglandin F2: A
new and independent predictor of peripheral arterial
disease”
We read with great interest the important paper by Mueller et
al1 who demonstrated that serum 8-iso-prostaglandin F2 is an
independent risk factor for peripheral arterial disease. We would
like to convey some of our own findings, which may be of mech-
anistic and therapeutic relevance.
First, we demonstrated that 8-isoprostane F2 up-regulates
nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase expression in vascular tissue and as such, promotes the
formation of superoxide.2 Superoxide elicits a number of vascu-
lopathic effects, including the inhibition of nitric oxide (NO)
bioavailability, endothelial cell apoptosis, and lipid peroxida-
tion.3 Since these are all components of peripheral arterial
disease, the potential for NADPH oxidase to promote vascu-
lopathy is clear. In turn, since superoxide itself promotes the
formation of 8-isoprostane F2, a self-perpetuating cycle may
ensue that results in the further generation of oxidative stress.2
In a more recent study, we found that superoxide itself pro-
motes NADPH oxidase expression, further augmenting this
cycle.4
These oxidative reactions also result in a reduction of endog-
enous vascular prostacyclin (PGI2) formation.
2 PGI2 is vasculopro-
tective in that it counters the actions of 8-isoprostane F2, in
particular, the inhibition of platelet and leukocyte activity and
adhesion.2 In this context, we found that the PGI2 analogue,
iloprost, is a potent inhibitor NADPH oxidase up-regulation elic-
ited by 8-isoprostane F2.
2 These data therefore indicate that
NADPH oxidase upregulation results in an imbalance between
8-isoprostane F2 and PGI2 that would favor intravascular oxida-
tive stress and vasculopathy.
In contrast, we found that aspirin had no effect on NADPH
oxidase expression.5 Because 8-isoprostane F2 is formed by
an oxidative pathway and not by cyclooxygenase,1,2 aspirin
may have little effect on 8-isoprostane F2 formation. This
may explain, in part, why aspirin is not optimally effective in
treating peripheral vascular disease or the clinical complica-
tions associated with the condition.6 However, we found that
NO-donating aspirins were potent inhibitors of NADPH oxi-
dase expression, an effect mediated by the NO moiety of the
drug.5
In more recent studies, we also found that homocysteine
augments the formation of 8-isoprostane F2 in arteries from
experimental diabetic models through an NADPH oxidase-super-
oxide mediated mechanism (Jeremy, unpublished observations).
Since homocysteine and diabetes mellitus are both risk factors for
peripheral vascular disease, this further consolidates the potentially
key role played by oxidative stress and 8-isoprostane F2 in the
etiology of peripheral arterial disease.
From a therapeutic perspective, it would be expected that
thromboxane A2 (TXA2) receptor antagonists may be useful in
treating peripheral vascular disease, because 8-isoprostane F2
activates the TXA2 receptor.
1,2 One possible problem is that
factors other than 8-isoprostane F2, including angiotensin II,
cytokines and hypoxia, upregulate NAPDH oxidase. However,
treatment with a TXA2 antagonist could be augmented by the
co-administration of iloprost (or an oral equivalent, such as
beraprost) in combination with NO-aspirin, an NADPH oxi-
dase inhibitor, or both. Such possibilities warrant further con-
sideration.Jaime Y. Jeremy, PhD
Saima Muzaffar, PhD
Gianni D. Angelini, PhD
Nilima Shukla, PhD
Bristol Heart Institute
University of Bristol
Bristol, United Kingdom
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Reply
We thank Dr Jeremy and colleagues for their kind interest in
our recent article demonstrating that increased oxidative stress, as
measured by 8-iso-prostaglandin F2, may be associated with
peripheral arterial disease. In this context, we appreciate the results
of the mechanistic experiments by Dr Jeremy and colleagues
summarized in their letter to the editor.
Considering the proposed therapeutic implications of in-
creased oxidative stress in peripheral arterial disease, Dr Jeremy and
colleagues mainly refer to prostacyclin analogues, nitric oxide-
donating nonsteroidal antiinflammatory drugs, and thromboxane
A2 receptor antagonists. However, although superoxide dismutase
mimetics, thiols, xanthine oxidase, and nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase inhibitors are currently
receiving much interest in developing strategies to reduce oxida-
tive stress in atherosclerosis, we would like to point out the
evidence that drugs in common clinical use, like 3-hydroxy-3-
methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors (sta-
tins), angiotensin-converting enzyme (ACE) inhibitors, and an-
giotensin II type 1 (AT1)- receptor blockers may also lower
oxidative stress.
A number of clinical trials have shown that statins improve
endothelial dysfunction in patients with coronary risk factors be-
yond what could be attributed to their impact on plasma lipids.1
The pleiotropic effects of statins include improvement of endothe-
lial dysfunction, increased nitric oxide bioavailability, antioxidant
properties, inhibition of inflammatory responses, and stabilization
of atherosclerotic plaques.2,3 ACE inhibitors and AT1-receptor
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properties.4,5
Many of the risk factors that predispose to atherosclerosis can
also cause endothelial dysfunction, and the presence of multiple
risk factors, such as hypercholesterolemia, arterial hypertension,
smoking, diabetes mellitus, and obesity, has been found to predict
endothelial dysfunction.1 Thus, it is conceivable that the modifi-
cation of these risk factors should be a further therapeutical ap-
proach to reduce oxidative stress. A better understanding of the
complexity of cellular redox reactions and the development of
sensitive and specific biomarkers that can be used clinically to assess
the oxidative stress phenotypes might improve strategies in the
treatment and prevention of atherosclerosis in the future.
Thomas Mueller, MD
Meinhard Haltmayer, MD
Department of Laboratory Medicine
Konventhospital Barmherzige Brueder
Linz, Austria
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Regarding “Deep venous thrombosis after
radiofrequency ablation of greater saphenous vein”
The recent article by Hingorani et al (J Vasc Surg 2004;40:
500-4) reports a 16% (12/73) incidence of deep vein thrombosis
in patients undergoing radiofrequency ablation of incompetent
great saphenous veins for symptomatic venous insufficiency. This is
a disturbing statistic considering the many individuals who suffer
from this disorder and the potential benefit radiofrequency abla-
tion can offer over ligation and stripping of the great saphenous
vein. Scrutiny of the article did not provide insight into why this
group of patients had such a high complication rate.
At Jobst Vascular Center, we have had a relatively large
experience with this same procedure (approximately 1500 cases)
for similar indications. Our deep vein thrombosis rate is 0.3%.
Some technical points that we incorporate that may differ from the
article are mentioned for consideration:
1. A limited coagulopathy screen (at least an activated protein C
resistance) is ordered preoperatively for any patient with a history
of thrombophlebitis, deep vein thrombosis, or a family history of
deep vein thrombosis.
2. For patients at risk, low-molecular-weight heparin is adminis-
tered postoperatively, and Coumadin also, if necessary.
3. All patients are scanned intraoperatively after radiofrequency
ablation and postoperatively within 5 days if the saphenofemoral
junction was not ligated. Although initially we ligated the saphe-
nofemoral junction 87% of the time, the percentage of cases we
ligate has decreased significantly.
4. A guidewire (0.025 inch) is used only if difficulty is encoun-
tered passing the catheter so as to minimize endothelial injury to
the common femoral vein caused by a foreign body in a un-
anticoagulated patient. Efforts are made to keep the wire and
catheter out of the deep venous system.5. The radiofrequency electrodes are positioned just below the
inferior epigastric vein, and once in place, the leg is not moved
during the first 10 cm of pullback. Flexion of the knee and
abduction of the hip can cause significant advancement of the
electrodes into the deep venous system.
6. Tumescent anesthesia is generously administered (250 to
400 mL) with particular attention to injecting directly over the
electrodes at the inferior epigastric vein level to ensure that the
great saphenous vein is compressed against the catheter near the
saphenofemoral junction.
7. We prefer 6F catheters, even for larger diameter veins, because
with precise, generous tumescence, good vein wall/electrode con-
tact can be achieved.
8. Increasing the catheter temperature to 90°Cmay increase collagen
denaturation and lumen shrinkage and has not been associated with
skin burns or saphenous nerve injuries in our patients.
We appreciate the willingness of Dr Hingorani and colleagues
to share their preliminary results with us. We would hope that they
would consider reporting subsequent results, perhaps as a letter to
the editor, since, as they so aptly mention in their article, “the
procedure has the promise of improving the care of many of our
patients.”
Steven S. Gale, MD, FACS
Steven M. Dosick, MD, FACS
Andrew J. Seiwert, MD, FACS
Anthony J. Comerota, MD, FACS, RVT
Jobst Vascular Center
Toledo, Ohio
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The protocol at the Jobst Vascular Center includes a limited
coagulopathy screen, an interesting addition that may identify
higher-risk patients. Furthermore, the addition of a ligation at the
saphenofemoral junction in 87% of a segment of the patients also
may add a level of protection from propagation into the common
femoral vein.
Not all of our surgeons use the guidewire, as often the probe
will pass easily up to the proximal saphenous vein in many patients.
We agree with the amount of tumescent that should be used,
as we have had a similar experience with the volume used, and that
the leg should not be moved after the probe has been positioned.
In addition, after the tumescent has been administered, we also
recheck the position of the probe with duplex imaging before
initiating the ablation.
We have also increased the catheter temperature to 90°C but
still continue to encounter the same degree of postoperative deep
venous thrombosis, despite multiple subsequent visits by the proc-
tors to recheck our technique.
Again, we do still believe in the benefits of the technique and
still continue to perform the technique, even in older patients with
CEAP classifications of 4, 5, and 6. When these deep venous
thromboses have been encountered, they resolve with the outpa-
tient administration of subcutaneous low-molecular-weight hepa-
rin. As more centers are using minimally invasive techniques to
ablate the refluxing saphenous vein, we look forward to examining
the published data of other centers.
Anil Hingorani, MD
Maimonides Medical Center
Brooklyn, NYdoi:10.1016/j.jvs.2004.11.032
